Synaffix wins Best Platform Technology at 7th Annual World ADC Awards

AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

● Multi-year strategic collaboration in target discovery and therapeutic developmentbased on Scenic Biotech’s disease modifying approach● Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse ofgenetic modifiers● Scenic Biotech will receive an...

Synaffix Announces Expansion of Collaboration with ADC Therapeutics

AMSTERDAM, NETHERLANDS – July 23, 2020 – Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its...

Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer

Amsterdam, The Netherlands, 1 July 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that Dr C....

BioGeneration Ventures closes BGV IV fund at €105 million

Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq   Investment focus on entrepreneurial innovation in therapeutics in Europe Total assets under management >€220 million ($250m) Naarden, The...